Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE 3
2021-000205-24Phase 2Terminated
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trilaciclib and avelumab in transitional cell carcinoma (TCC) (2 arms), sponsored by G1 Therapeutics, Inc. Primary endpoint: Progression-free survival. Started Jun 2021; status: terminated.
02
Drugs
trilaciclibavelumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2021-000205-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000205-24.